Figure 4: Time to First Occurrence of Hospitalization for Heart Failure or CV Death in the DECLARE Trial Figure 5: Time to First Occurrence of Hospitalization for Heart Failure in the DECLARE Trial 14.4 Chronic Kidney Disease The Trial to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD, NCT03036150) was an international, multicenter, randomized, double-blind, placebo-controlled trial in adult patients with chronic kidney disease (CKD) (eGFR between 25 and 75 mL/min/1.73 m2) and albuminuria [urine albumin creatinine ratio (UACR) between 200 and 5000 mg/g] who were receiving standard of care background therapy, including a maximally tolerated, labeled daily dosage of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
Third-Party Tested Public COAs Batch Verified EU Shipping Related Products 49,00 89,00 79,00 59,00
Dosage and Administration: Professional guidance should be sought for injection forms
Proper dosing is essential, but real-world titration is often less systematic than clinical trial protocols
Exendin-4 Stimulates Islet Cell Replication via the IGF1 Receptor Activation of Mtorc1/S6K1
)
